Scaling LNP Formulation for Clinical-Grade RNA Therapeutics
PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES
Scaling LNP Formulation for Clinical-Grade RNA Therapeutics
CELL & GENE | RNA | BIOLOGICS
Proven Intelligence in RNA Delivery Systems.
Executive Summary
Scaling lipid nanoparticle (LNP) formulation from research to GxP-compliant manufacturing presents a significant bottleneck for RNA therapeutic programs. Traditional batch-based methods often fail to produce the consistent particle size, polydispersity, and encapsulation efficiency required for clinical use. Franklin Biolabs employs advanced microfluidic-based continuous flow systems to ensure precise, reproducible LNP production, enabling a more direct path to successful IND submissions for mRNA, siRNA, and gRNA payloads. This approach, supported by our >100,000 sq ft facilities, is designed to meet harmonized international guidelines (ICH) and accelerate typical 18-24 month IND timelines.
Frequently Asked Questions
What are the primary challenges when scaling lipid nanoparticle (LNP) formulation for clinical trials?
The primary challenge is maintaining consistent particle characteristics : size, charge, and encapsulation efficiency : when moving from small-scale discovery batches to larger, clinical-grade production volumes. Traditional mixing methods often introduce variability, which can impact the therapeutic’s biodistribution, potency, and safety profile, creating risks for multi-jurisdictional IND submissions.
How does microfluidic technology improve the consistency of RNA therapeutics for IND-enabling studies?
Microfluidic systems provide precise, controllable mixing of lipid and aqueous phases at a nanoliter scale. This results in highly uniform LNPs with low polydispersity, a fundamental quality attribute (CQA) for regulatory bodies. This level of control ensures batch-to-batch reproducibility, which is foundational for robust IND-enabling toxicology studies and chemistry, manufacturing, and controls (CMC) data packages.
What analytical capabilities are required to characterize LNPs for a clinical-grade RNA program?
A comprehensive analytical strategy is needed to characterize LNP-RNA products. Key assays include dynamic light scattering (DLS) for particle size and polydispersity, zeta potential for surface charge, and fluorescence-based assays (e.g., RiboGreen) for encapsulation efficiency. Cryo-transmission electron microscopy (cryo-TEM) is also used to assess particle morphology and structure.
Transitioning from Bench-Scale to Clinical-Scale LNP Production
The successful clinical translation of RNA therapeutics depends directly on the robustness of the LNP delivery vehicle. While bench-scale formulations may achieve proof-of-concept, scaling these processes for clinical supply introduces significant technical hurdles. Inconsistent mixing parameters in larger vessels can lead to heterogeneous particle populations, compromising both efficacy and safety.
Franklin Biolabs addresses this challenge by moving beyond conventional T-junction or bulk mixing methods. We utilize parallelized microfluidic device technology to achieve superior control over particle formation, ensuring that LNPs produced at scale retain the exact physicochemical properties defined during process development.
The Impact of Controlled Formulation on Therapeutic Potency
The method of LNP assembly directly influences the in vivo performance of the RNA payload. A well-formed LNP protects the RNA from degradation and facilitates efficient cellular uptake and endosomal escape.
-
Reproducibility: Continuous flow manufacturing minimizes the batch-to-batch variability common in bulk emulsification techniques.
-
Potency: Uniform particle size and high encapsulation efficiency correlate with improved in vivo delivery and gene expression or knockdown.
-
Scalability: Parallelized systems allow for a linear increase in production volume without re-optimizing formulation parameters.
This approach is validated by research demonstrating that LNPs generated via scalable microfluidic devices exhibit superior in vivo potency compared to those produced by traditional methods (PMID: 34189917). This has a direct translational impact, reducing risk in non-target tissue biodistribution assessments and strengthening the data package for global regulatory submissions.
A Framework for Regulatory Success
Our scientific leadership and core operational team have a history of achieving a 100% successful IND rate since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024. This experience, which includes foundational work with partners like Moderna, informs our phase-appropriate approach to CMC for RNA therapeutics. We develop and qualify all analytical assays under GxP conditions, building a data-driven narrative that satisfies FDA, EMA, and other international regulatory bodies.
This focus on scalable, reproducible manufacturing is a core component of our broader vector services. For programs involving different modalities, explore our work in Large-Scale AAV Manufacturing and Process Development.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.